89 related articles for article (PubMed ID: 11572652)
21. Novel bacterial acetyl coenzyme A carboxylase inhibitors with antibiotic efficacy in vivo.
Freiberg C; Pohlmann J; Nell PG; Endermann R; Schuhmacher J; Newton B; Otteneder M; Lampe T; Häbich D; Ziegelbauer K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2707-12. PubMed ID: 16870762
[TBL] [Abstract][Full Text] [Related]
22. Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
Hirokawa Y; Kinoshita H; Tanaka T; Nakata K; Kitadai N; Fujimoto K; Kashimoto S; Kojima T; Kato S
J Med Chem; 2008 Apr; 51(7):1991-4. PubMed ID: 18330977
[TBL] [Abstract][Full Text] [Related]
23. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
25. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
26. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
28. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Streit JM; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
[TBL] [Abstract][Full Text] [Related]
29. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
30. Potent antibacterial activity of halogenated compounds against antibiotic-resistant bacteria.
Vairappan CS; Kawamoto T; Miwa H; Suzuki M
Planta Med; 2004 Nov; 70(11):1087-90. PubMed ID: 15549668
[TBL] [Abstract][Full Text] [Related]
31. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.
Scheinfeld N
J Drugs Dermatol; 2007 Jan; 6(1):97-103. PubMed ID: 17373167
[TBL] [Abstract][Full Text] [Related]
32. The interaction of coumarin antibiotics with fragments of DNA gyrase B protein.
Gormley NA; Orphanides G; Meyer A; Cullis PM; Maxwell A
Biochemistry; 1996 Apr; 35(15):5083-92. PubMed ID: 8664301
[TBL] [Abstract][Full Text] [Related]
33. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
Pfaller MA; Beach ML; Gordon KA; Jones RN
J Chemother; 2002 Feb; 14(1):13-8. PubMed ID: 11892893
[TBL] [Abstract][Full Text] [Related]
34. Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents.
Takhi M; Singh G; Murugan C; Thaplyyal N; Maitra S; Bhaskarreddy KM; Amarnath PV; Mallik A; Harisudan T; Trivedi RK; Sreenivas K; Selvakumar N; Iqbal J
Bioorg Med Chem Lett; 2008 Sep; 18(18):5150-5. PubMed ID: 18768315
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationship in two series of aminoalkyl substituted coumarin inhibitors of gyrase B.
Laurin P; Ferroud D; Schio L; Klich M; Dupuis-Hamelin C; Mauvais P; Lassaigne P; Bonnefoy A; Musicki B
Bioorg Med Chem Lett; 1999 Oct; 9(19):2875-80. PubMed ID: 10522710
[TBL] [Abstract][Full Text] [Related]
36. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria.
Hadjivassileva T; Thurston DE; Taylor PW
J Antimicrob Chemother; 2005 Sep; 56(3):513-8. PubMed ID: 16024592
[TBL] [Abstract][Full Text] [Related]
37. DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives.
Bürli RW; McMinn D; Kaizerman JA; Hu W; Ge Y; Pack Q; Jiang V; Gross M; Garcia M; Tanaka R; Moser HE
Bioorg Med Chem Lett; 2004 Mar; 14(5):1253-7. PubMed ID: 14980676
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
[TBL] [Abstract][Full Text] [Related]
40. [Bacterial type II topoisomerases as targets for antibacterial drugs].
Pietrusiński M; Staczek P
Postepy Biochem; 2006; 52(3):271-82. PubMed ID: 17201062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
